afami-cel
adaptimmune
['afami-cel', 'sarcoma', 'pivotal', 'adaptimmune']
today is the first day of #asco22 where we will present a poster showing longer pfs in a pooled analysis of patients with synovial sarcoma and mrcls treated with afami-cel in the pivotal spearhead-1 and phase 1 trials. #cancer #celltherapy #immunotherapy 
Adaptimmune is a multinational, clinical-stage #biotech company focused on developing novel immunotherapies that can potentially transform cancer treatment